How CJC-1295 No-DAC Affects Prolactin

Prolactin is secreted by lactotrophs in the anterior pituitary. Its regulation is controlled primarily by dopamine (prolactin-inhibiting factor) and TRH (which stimulates prolactin). GH-axis peptides interact with prolactin only if they activate pathways that modify dopamine or TRH signalling, or if they directly stimulate lactotrophs.

CJC-1295 no-DAC has no mechanism for prolactin interaction:

1. GHRH receptor tissue restriction: GHRH-R is expressed on somatotrophs, not lactotrophs. Binding CJC-1295 no-DAC to GHRH-R activates only the somatotroph cAMP-PKA pathway, with no paracrine or endocrine signal that reaches lactotrophs.
2. Absence of GHS-R1a activation: The ghrelin receptor (GHS-R1a) is the common pathway by which GHRP-6 and hexarelin elevate prolactin. CJC-1295 no-DAC is a GHRH analog, not a GHS-R1a agonist, and therefore lacks this prolactin-stimulating mechanism entirely.
3. Ipamorelin as the co-component: When CJC-1295 no-DAC is combined with ipamorelin (the standard protocol), ipamorelin's pituitary selectivity also protects against prolactin elevation. Raun et al. (1998, PMID 9849822) confirmed that ipamorelin does not elevate prolactin even at 200 times the effective GH dose.
4. Contrast with GHRP-6: GHRP-6 at clinical doses elevates prolactin through GHS-R1a activation in lactotrophs, which can contribute to libido issues, gynecomastia risk, and galactorrhoea in sensitive users. The CJC-1295 no-DAC plus ipamorelin stack eliminates this risk.

Standard protocol (100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin, 1-2 times daily):

• Serum prolactin: no change expected; normal male range approximately 2 to 14 ng/mL
• No prolactin-related side effects expected: no gynecomastia risk from prolactin, no libido suppression from prolactin elevation

Contrast with non-selective GHRPs:

• GHRP-6 (100 mcg): elevates prolactin transiently in some users; documented in multiple pharmacological studies
• Hexarelin: prolactin-elevating at clinical doses
• Ipamorelin: no prolactin elevation (Raun 1998)
• CJC-1295 no-DAC: mechanistically prolactin-neutral

Routine prolactin monitoring is not required for CJC-1295 no-DAC protocols. There is no mechanistic basis for prolactin elevation.

When to check prolactin:

• If gynecomastia or galactorrhoea develops in the absence of other prolactin-elevating compounds (nandrolone, trenbolone, antipsychotics, antidepressants). These symptoms are almost certainly driven by another compound.
• If transitioning from GHRP-6 or other non-selective GHRPs where prolactin was previously elevated: check baseline at transition and 4 to 6 weeks post-switch to confirm normalisation.
• Annual comprehensive hormone panel including prolactin is reasonable practice for long-term GH peptide users, not specifically because of CJC-1295 no-DAC.

No prolactin-specific management is required for CJC-1295 no-DAC.

If elevated prolactin is detected while on a CJC-1295 no-DAC protocol:

• CJC-1295 no-DAC is not the driver; investigate other causes: nandrolone, trenbolone, antipsychotics, stress, prolactinoma, hypothyroidism, renal failure
• Cabergoline 0.25 to 0.5 mg twice weekly is the standard intervention for drug-induced hyperprolactinaemia from AAS use

Switching from GHRP-6 to CJC-1295 no-DAC plus ipamorelin:

• Any prolactin elevation from GHRP-6 use typically resolves within 2 to 4 weeks of switching
• Gynecomastia-related breast tissue, if developed, may require more than prolactin normalisation to reverse; the estrogen component from concurrent AAS is the more important target